Clinical Neurology: Brief Report

Bolchini M. · Schiano di Cola F. · Ceccardi G. · Caratozzolo S. · Liberini P. · Rao R. · Padovani A.

Author affiliations

Neurology Unit, Department of Clinical and Experimental Sciences, Università degli Studi di Brescia and ASST Spedali Civili Brescia, Brescia, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: August 26, 2022
Accepted: October 12, 2022
Published online: December 20, 2022

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Abstract

The aim of the present study was to assess erenumab efficacy in migraine disability and intensity throughout the first treatment cycle, discontinuation, and the first 6 months of re-treatment in patients with high-frequency episodic migraine. The study design was retrospective and observational. Inclusion criteria were the following: diagnosis of high-frequency episodic migraine and ongoing treatment with erenumab 140 mg currently at their second treatment cycle. Data regarding migraine frequency, disability (MIDAS score), and severity of attacks (NRS score) were collected quarterly. Twenty-five patients were enrolled. At the end of the first treatment cycle, compared to baseline, a significant improvement of MIDAS scores was found (13.5 ± 11.1 vs. 72.5 ± 32.1; p = 0.005), with a subsequent worsening during treatment suspension (30.1 ± 26.9; p = 0.03). Pain intensity remained unmodified during the first treatment cycle (NRS score baseline: 7.6 ± 0.9 vs. 12 months: 7.5 ± 0.7; p = 0.13). During re-treatment, MIDAS scores documented a new significant improvement, reaching the same level at 6 months of re-treatment as at the end of the first cycle (30.1 ± 26.9 vs. 12.9 ± 5.4; p = 0.03). A significant improvement, compared to baseline, was observed for pain intensity during re-treatment (6.8 ± 2.2 vs. 5.6 ± 0.9 at RT3 vs. 5.2 ± 1.4 at RT6; p = 0.05). In conclusion, during re-treatment with erenumab 140 mg, migraine pain intensity and disability documented a significant and progressive improvement. Our data confirm the long-term efficacy, although in a very limited case series, of monoclonal antibodies targeting CGRP beyond headache frequency reduction.

© 2022 S. Karger AG, Basel

References Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. Goadsby PJ, Evers S. International classification of headache disorders: ICHD-4 alpha. Cephalalgia. 2020;40(9):887–8. Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56(8):1280–9. Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. 2020;40(4):399–406. Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: a systematic review. Headache. 2019;59(3):306–38. Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61(7):992–1003. Buse DC, Reed ML, Fanning KM, Bostic RC, Lipton RB. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American migraine prevalence and prevention (AMPP) study the American migraine prevalence and prevention (AMPP) study. Headache. 2020;60(10):2340–56. Irimia P, García-Azorín D, Núñez M, Díaz-Cerezo S, de Polavieja PG, Panni T, et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study. J Headache Pain. 2022;23(1):78. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018 Nov 24;392(10161):2280–7. Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, et al. Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache. 2021 Feb;61(2):363–72. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425–34. Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020 Apr 7;21(1):32. Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, et al. Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci. 2020 Dec;41(S2):489–90. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021 May;28(5):1716–25. Goadsby PJ, Reuter U, Lanteri-Minet M, Paiva da Silva Lima G, Hours-Zesiger P, Fernandes C, et al. Long-term efficacy and safety of erenumab: results from 64 Weeks of the LIBERTY study. Neurology. 2021 Apr 28;96(22):e2724–35. Schiano di Cola F, Caratozzolo S, Venturelli E, Balducci U, Sidoti V, Pari E, et al. Erenumab discontinuation after 12-month treatment: a multicentric, observational real-life study. Neurol Clin Pract. 2021 Dec;11(6):e834–9. Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain. 2021 Dec 18;22(1):154. Guerzoni S, Baraldi C, Pensato U, Favoni V, Lo Castro F, Cainazzo MM, et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci. 2022 Jun;43(6):3823–30. Lipton RB, Dodick DW, Kudrow D, Reuter U, Tenenbaum N, Zhang F, et al. Reduction in migraine pain intensity in patients treated with erenumab: a post hoc analysis of two pivotal randomized studies. Cephalalgia. 2021 Dec;41(14):1458–66. Article / Publication Details

First-Page Preview

Received: August 26, 2022
Accepted: October 12, 2022
Published online: December 20, 2022

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 1

ISSN: 0014-3022 (Print)
eISSN: 1421-9913 (Online)

For additional information: https://www.karger.com/ENE

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.